New Stocks To Watch In Biotech, Tech & More
Companies involved in life sciences (including for COVID-19), home healthcare and cell therapies are among the six new biotech stocks to watch.
Companies involved in life sciences (including for COVID-19), home healthcare and cell therapies are among the six new biotech stocks to watch.
A rectangle pattern has formed for the biotech stock featured in today’s article, and the author advises that “When this pattern is broken, a breakout or breakdown is expected.”
“If you only have enough time to keep up with a handful of biotech catalysts that are on the way soon, these three are well worth your attention.”
Regarding the two stocks he highlights, the author of today’s article declares “these two small-caps are both first movers in healthcare sectors that are ripe for disruption, with massive opportunities over the next decade.”
RAS mutations are the initiating genetic events in many cancers – and have proven to be extremely difficult to target. With its lead compound, however, the oncology company featured in today’s article is “looking to become the backbone of treatment for RAS-driven cancers.
When you think of infrastructure, you likely think of things such as roads, bridges and airports. But the infrastructure plan the Biden Administration just rolled out also includes hundreds of billions of dollars in funding for health care infrastructure.
A clinical-stage company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases is among the three new biotech stocks to watch.
Among the three top biotech stocks to buy right now, as identified by the author of today’s article, is a company that he argues “deserves… Read More »“The Overall Best Biotech Around” – And 2 Other Top Biotech Stock Picks
Is the current downturn a good buying opportunity for biotech stocks? And, if so, which biotech stocks are the most promising picks for aggressive investors?
Two penny stocks that boast “Strong Buy” consensus ratings from the analyst community and massive upside potential.